Arcadia Biosciences Q1 revenue $1.5M (down 53% YoY) but gross profit improves $922k

Arcadia Biosciences, Inc.

2023-Q1 EPS reported -$10.86 revenue$1,509,000

Total revenues $1.5M vs $3.2M; prior year included $1.8M in discontinued products.
Loss from operations improved to $4.0M from $4.6M; operating expenses fell 29% to $5.6M.
Cost of revenues down to $825k from $3.5M, driving $922k gross profit improvement.
Private placement financing impact on net loss still under review; Q1 10-Q to be filed next week.
GoodWheat pasta named 'Best New Product' by Retail Dietitians Business Alliance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.5

Arcadia Biosciences, Inc. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021303

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.